Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Rhabdomyolysis prevails as a potentially fatal and rare complication of statin therapy. One of its main adverse outcomes is acute kidney injury (AKI) due to myoglobin accumulation, which may require renal replacement therapy (RRT) and carries a high risk of mortality. In recent years, several alternatives targeting myoglobin clearance have been explored, including hemoadsorption with CytoSorb® filters and continuous veno-venous hemofiltration (CVVHF). These therapies represent alternative therapies to severe cases of AKI and rhabdomyolysis secondary to statin use.
An 80 year old woman with a history of hypertension, type 2 diabetes, hyperlipidemia, osteoarthrosis and fibromyalgia consulted at the emergency department complaining of intense generalized myalgias and rapidly progressing weakness. Initial studies revealed creatine kinase (CK) levels of 35.648 U/L, serum creatinine of 3.0 mg/dL and BUN of 46.9 mg/dL. Aggressive IV crystalloid therapy was started, followed by a single 72-hour session of CVVHF and a 12-hour session of hemoadsorption with CytoSorb® filter (Images 1 and 2). Blood CK and creatinine levels were monitored afterwards, documenting a progressive descent in serum CK to a level of 325.2 U/L and normalization of creatinine levels (1.1 mg/dL) (Chart 1). The patient was discharged days later with no need for additional RRT.
Severe rhabdomyolysis secondary to statin use is a rare condition, however it has a high risk of complications and a high mortality rate especially in comorbid older adults. Conventional treatment is based on aggressive IV fluid resuscitation and urinary alkalinization, however these methods may be insufficient in cases of severe rhabdomyolysis-related AKI. Novel techniques like hemoadsorption and CVVHF allow an effective clearance of myoglobin thanks to its low molecular weight. This case highlights the potential effectiveness of these therapies in cases of rapid renal deterioration.
Hemoadsorption with CytoSorb® represents a promising new alternative for the management of severe rhabdomyolysis-related AKI. In the case of our patient, the early use of these therapies warranted a favorable outcome free of complications. Further studies are required to establish its widespread use in this context.
